| Literature DB >> 30140038 |
Mariusz Dąbrowski1,2, Grażyna Mielnik-Niedzielska3, Andrzej Nowakowski4.
Abstract
Type 1 diabetes can lead to impaired function of many organs and tissues. The aim of this study was to evaluate associations between hearing and kidney function in young adult type 1 diabetic patients. 31 patients (9 women) with type 1 diabetes, aged <45, with disease duration <10 years were included. Blood and urine samples for laboratory tests and urinary albumin excretion (UAE) assessment were obtained. eGFR was calculated with CKD-EPI formula. In all patients pure-tone audiometry, transient evoked otoacoustic emissions and auditory brainstem responses were evaluated, also eye fundus was examined. Mean patients' age was 29.5 ± 7.0 years and disease duration 4.6 ± 2.6 years. All patients had eGFR > 60.0 ml/min/1.73 m2. In one case microalbuminuria and in 3 patients early retinopathy were revealed. Linear correlation between eGFR and hearing threshold at 4, 6, 8 and 12 kHz was found. Patients with hearing impairment (n = 7) had lower eGFR 108.8 vs. 121.7 ml/min/1.73 m2, p = 0.047 compared to normal-hearing subjects. Also patients with absence of otoacoustic emissions in at least one ear had lower eGFR, 103.1 vs. 123.3 ml/min/1.73 m2, p < 0.001, compared to the remaining group. In auditory brainstem responses we found significant linear correlation between eGFR and wave III and interval I-III latencies, and between UAE and waves III, V and interval I-III latencies. This study suggests existence of relationship between hearing and kidney function in type 1 diabetic patients. Pathways directly linking hearing and renal function are unknown. Larger studies are necessary to further analyze these relationships.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30140038 PMCID: PMC6107493 DOI: 10.1038/s41598-018-31057-6
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Characteristics of the study participants.
| Parameter | Mean | Standard Deviation | Range |
|---|---|---|---|
| Creatinine (μmol/L) | 66.30 | 17.68 | 35.36–106.08 |
| eGFR CKD-EPI (mL/min/1.73 m2) | 118.75 | 21.44 | 79–167.4 |
| Age (years) | 29.52 | 6.96 | 18–43 |
| Gender | |||
| Male, n (%) | 22 (71.0%) | N/A | N/A |
| Female, n (%) | 9 (29.0%) | ||
| Diabetes duration (months) | 55.7 | 31.3 | 3–117 |
| HbA1c (mmol/mol) | 61.8 | 16.6 | 31.1–109.8 |
| HbA1c (%) | 7.80 | 1.50 | 5–12.2 |
| Urinary albumin excretion (mg/L) | 9.51 | 7.88 | 5–43.3 |
| Total cholesterol (mmol/L) | 4.67 | 1.02 | 2.72–7.17 |
| HDL-cholesterol (mmol/L) | 1.50 | 0.38 | 0.62–2.23 |
| LDL-cholesterol (mmol/L) | 2.67 | 0.98 | 0.57–4.97 |
| Triglycerides (mmol/L) | 1.03 | 0.77 | 0.38–3.60 |
| Retinopathy, n (%) | 3 (9.7%) | N/A | N/A |
| SBP (mm Hg) | 130.4 | 11.9 | 104–156 |
| DBP (mm Hg) | 75.5 | 7.2 | 62–99 |
| Hypertension, n (%) | 8 (25.8%) | N/A | N/A |
| BMI (kg/m2) | 23.05 | 3.36 | 18.6–34.1 |
| Hearing impairment, n (%) | 7 (22.6%) | N/A | N/A |
| Mean TEOAE amplitude at 1.2–3.5 kHz (dB) | 7.74 | 4.43 | 0.1–20.3 |
| TEOAE absent, n (%) | 7 (22.6%) | N/A | N/A |
| Wave I latency (ms) | 1.73 | 0.12 | 1.55–2.00 |
| Wave III latency (ms) | 3.91 | 0.19 | 3.50–4.35 |
| Wave V latency (ms) | 5.78 | 0.25 | 5.10–6.30 |
| Interval I-III latency (ms) | 2.17 | 0.16 | 1.80–2.50 |
| Interval III-V latency (ms) | 1.85 | 0.16 | 1.45–2.10 |
| Interval I-V latency (ms) | 4.03 | 0.20 | 3.55–4.40 |
Figure 1Linear correlation between eGFR and hearing thresholds at 4000 Hz, 6000 Hz, 8000 Hz and 12,000 Hz (scatter plot, regression lines and 95% confidence intervals).
Figure 2Linear correlation between eGFR and wave III and interval I-III latencies (scatter plot, regression lines and 95% confidence intervals).
Figure 3Linear correlation between urinary albumin excretion and wave III, wave V and interval I-III latencies (scatter plot, regression lines and 95% confidence intervals).